Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Avatarhashon Jan 29, 2019 4:58pm
156 Views
Post# 29293134

RE:RE:Motley Fool posted

RE:RE:Motley Fool postedIf part 4&5 licence comes in next two weeks, the capacity will increase just in time for centre of excellence. That is where the difference is made. Aphria will be ready for roll out of edibles in october. We just need that HC licence soon.
Donbgamecock wrote:
Progressive wrote: That organigram is outperforming aphria...just wait until aphria releases there next quarter. Yes organigram did great but once the other release next month this sector is going to explode.


Without PIV getting licensed, we will not see a drastic increase from revenues from this last qtr.   Remember that last qtr’s big revenue stream was from selling LHS and Hiku for $85M.  Hopefully this qtr we’ll see some cost reductions and increased revenue from: selling more inventory, LATAM operations, and 1-1/2 months CC Pharma operations.  We wont be doubling revenue QOQ.  

Even if PIV were approved this week, first harvest and resulting revenues wont be seen until May.  1QTR2020 will be the first full reporting period for P1V.  This is why its so important for HC to get on the stick and get PIV and V approved.  The extraction center will also have to wait for approval. 


Bullboard Posts